Elsevier

Human Pathology

Volume 41, Issue 9, September 2010, Pages 1299-1309
Human Pathology

Original contribution
Clonal analysis of bilateral, recurrent, and metastatic papillary thyroid carcinomas

https://doi.org/10.1016/j.humpath.2010.02.008Get rights and content

Summary

Papillary thyroid carcinoma usually presents as a multifocal disease; and tumors often recur in the contralateral thyroid lobe, raising questions concerning their clonal origins. The clonality of tumors appearing simultaneously in both lobes or recurring in the contralateral lobe remains unknown. Accordingly, we examined 25 pairs of bilateral papillary thyroid carcinomas (synchronous or metachronous) and 15 matched metastatic lymph nodes. BRAF gene mutation analysis combined with X-chromosome inactivation was used to evaluate these tumors' clonal origins. Genomic DNA was prepared from paraffin-embedded tissues after microdissection. In total, 62 tumors yielded DNA of adequate quality. Eighteen (18/21, 85.7%) of 21 informative cases showed concordant BRAF status in tumors from both thyroid lobes, being either BRAF mutation positive (12 patients) or BRAF mutation negative (6 patients). Metastatic lymph nodes in 12 patients (12/15, 80%) had a complete concordance of BRAF state with their primaries. Of the 18 studied female patients, 11 were suitable for X-chromosome inactivation assay. Nine cases (9/11, 81.1%) showed the same pattern of inactivation in bilateral tumors. A close correlation was found between BRAF mutation and X-chromosome inactivation analysis. In conclusion, our data provide evidence that bilateral, recurrent, and metastatic papillary thyroid carcinomas often arise from a single clone and that intrathyroidal metastasis may play an important role in the development of bilateral tumors, as well as in the recurrence of this malignancy.

Introduction

Papillary thyroid carcinoma (PTC) is the most common histotype of thyroid cancer and accounts for about 1% of human malignancies [1]. Patients with PTC generally have a good prognosis, especially in those younger than 45 years at the time of diagnosis [2]. However, about 5% of patients with PTC experience a recurrence within 5 years after the initial treatment [3], [4]. In patients with local or distant recurrence after lobectomy, a tumor is found in more than 60% of the time in the resected contralateral lobe [5], [6]. In addition, PTC is often multifocal, with a reported frequency varying widely from 18% to 87%, among which 61% are bilateral [7], [8].

The clonal origin of multifocal PTC is still under debate. There are 2 different theories to address this issue. One is that these tumors are of monoclonal origin, arising from intrathyroidal metastasis of a clonal population of cells. The other is that the multiple foci are of independent origin and arise separately in a background of field cancerization. Distinguishing between these 2 theories will improve our understanding of both the biological mechanisms of multifocal PTC, as well as the possible reasons why PTC recurs. Several studies have been performed to investigate the clonality of tumors located in the same thyroid lobe with varied results [9], [10], [11], [12], [13]. The clonality of tumors occurring simultaneously in both thyroid lobes or that of recurrent tumors in the contralateral lobe remains unknown.

Previous studies have shown that PTC displays several highly prevalent genetic alterations, like mutations in BRAF or RAS, and rearrangements of the RET or NTRK1; among these alterations, mutations in the BRAF gene (exon 15-BRAFV600E) is the most common [14], [15], [16], [17], [18]. Because of its high prevalence and presumed early place as a genetic event in thyroid carcinogenesis [19], BRAFV600E mutation has been used as a marker for clonality analysis and has shown some advantage in evaluating the clonal origin of multifocal PTCs [12], [13]. However, few studied have combined this mutation with other methods based on changes established early enough to assess the clonality of tumors.

Determination of X-chromosome inactivation (XCI) has also been used to study clonality in many human tumors, including thyroid cancers [20]. According to the Lyon [21] hypothesis, 1 of the 2 X-chromosomes in all female somatic cells is randomly deactivated by the DNA methylation at CpG islands during early embryogenesis. Once established, the inactivated X-chromosome is stably transmitted from a parent cell to its progeny. Therefore, a given group of cells resulting from clonal expansion of a single progenitor shows the same pattern of XCI. Distinguishing the patterns of XCI permits investigators to determine whether multiple tumors in female subjects arise from one or more progenitors.

In this study, we investigated the clonality of bilateral PTCs (synchronous or metachronous) and metastatic lymph nodes by assaying for the presence or absence of the BRAF mutation. We also examined the XCI status in separate tumors in female patients. By combining the 2 strategies, genotypic clonality (BRAF mutations, involved in the malignant transformation) and phenotypic clonality (XCI, established in early embryogenesis), we reasoned that we could provide more definitive answers as to clonality in multifocal or recurrent PTCs.

Section snippets

Case selection and tumor specimen collection

A computer-based database comprising 809 patients was established to select eligible cases. These patients were admitted to the First Affiliated Hospital, Zhejiang University School of Medicine (Hangzhou, China), from 1997 to 2006 and underwent thyroidectomy for the treatment of thyroid carcinoma, with or without neck lymph node dissection. A list of cases was generated according to the following criteria: (a) bilateral or recurrent PTCs (including both primary and recurrent tumors) were

Clinical features of the study group

A total of 66 tumors from 25 patients (female, 18; male, 7) were analyzed in this study, among which 51 were bilateral tumors and 15 were metastatic lymph nodes. Twenty-two pairs were synchronous, whereas 3 pairs were metachronous (ie, recurrent, shown in Table 1). The mean age at diagnosis was 42.2 years (range, 14-75 years), and the median diameter of the studied tumors was 2.2 cm (range, 0.3-9.4 cm). Of the 3 recurrent PTCs, both the primary and recurrent tumors were studied; and the

Discussion

Multifocality is frequently observed in patients of PTC, with an increased risk of lymph node metastases and regional recurrence [7], [30]. However, as a specific subtype of multifocal PTCs, bilateral PTC has not been widely investigated. Studies of this subtype were just restricted to clinical observations [5], [6], [30], and the clonal origin of bilateral tumors remains unknown.

Most clonality studies on PTCs were done on multiple tumors located in one thyroid lobe [10], [12]. Only a few

Acknowledgment

We thank Ruokuo Han, Ruopeng Weng, and Zonglin Lin for patients' clinical follow-up, and Qixing Chen and Feng Zhang for technical assistance. We are also grateful to Dr Robert Wohlhueter (Centers for Disease Control and Prevention, Atlanta, GA; retired) for his contributions to the preparation of the manuscript.

References (35)

  • GriecoM. et al.

    PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas

    Cell

    (1990)
  • FranceschiS. et al.

    The epidemiology of thyroid carcinoma

    Crit Rev Oncog

    (1993)
  • TsangR.W. et al.

    The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma

    Cancer

    (1998)
  • FernandesJ.K. et al.

    Overview of the management of differentiated thyroid cancer

    Curr Treat Options Oncol

    (2005)
  • BilimoriaK.Y. et al.

    Extent of surgery affects survival for papillary thyroid cancer

    Ann Surg

    (2007)
  • PasiekaJ.L. et al.

    The incidence of bilateral well-differentiated thyroid cancer found at completion thyroidectomy

    World J Surg

    (1992)
  • PaciniF. et al.

    Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients

    Thyroid

    (2001)
  • KatohR. et al.

    Multiple thyroid involvement (intraglandular metastasis) in papillary thyroid carcinoma. A clinicopathologic study of 105 consecutive patients

    Cancer

    (1992)
  • IidaF. et al.

    Study of intraglandular dissemination of thyroid cancer

    Cancer

    (1969)
  • McCarthyR.P. et al.

    Molecular evidence for the same clonal origin of multifocal papillary thyroid carcinomas

    Clin Cancer Res

    (2006)
  • JovanovicL. et al.

    Most multifocal papillary thyroid carcinomas acquire genetic and morphotype diversity through subclonal evolution following the intra-glandular spread of the initial neoplastic clone

    Pathol

    (2008)
  • ShattuckT.M. et al.

    Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma

    N Engl J Med

    (2005)
  • GianniniR. et al.

    The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma

    J Clin Endocrinol Metab

    (2007)
  • ParkS.Y. et al.

    Analysis of differential BRAF(V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci

    Cancer

    (2006)
  • NikiforovaM.N. et al.

    Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis

    Expert Rev Mol Diagn

    (2008)
  • KimuraE.T. et al.

    High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma

    Cancer Res

    (2003)
  • HaraH. et al.

    N-ras mutation: an independent prognostic factor for aggressiveness of papillary thyroid carcinoma

    Surgery

    (1994)
  • Cited by (48)

    • Risks of central lymph node metastasis in papillary thyroid carcinoma with or without multifocality in at least one lobe: A multi-center analysis

      2022, Oral Oncology
      Citation Excerpt :

      When two or more foci of papillary thyroid carcinoma (PTC) are anatomically present in one or both thyroid lobes, it is deemed multifocal [3]. Studies have proven that multifocal lesions within the same thyroid gland are composed of multiple synchronous tumors that share the same clonal origin, manifesting through the intra-thyroid spread of a single primary tumor [8–11]. The reported incidence of multifocality amongst PTC patients is estimated to be around 18 %-87.5 % [4–7].

    • A UK based two-centre review of multifocality and its role in the treatment of papillary thyroid cancer

      2022, European Journal of Surgical Oncology
      Citation Excerpt :

      The reported incidence of multifocality varies widely between 18 and 87% in the literature, depending on the extent of scrutiny applied to the histological specimen [2]. Studies suggest that multifocality may either arise from multiple independent tumour origins or from intrathyroidal metastases from a single malignant cell [7,8]. The clonal origin of multifocal tumours could improve our understanding of disease pathogenesis, particularly if the presence of intrathyroidal metastases has the potential to indicate more aggressive behaviour, increased metastatic potential and worse prognosis [9].

    View all citing articles on Scopus

    Funding support: This study was supported by National Basic Research Program of China (973 Program, No. 2009CB521704) from the Ministry of Science and Technology of the People's Republic of China (Beijing, China).

    View full text